Cytolytic activity of the human papillomavirus type 16 E711-20 epitope-specific cytotoxic T lymphocyte is enhanced by heat shock protein 110 in HLA-A*0201 transgenic mice

Clinical and Vaccine Immunology

Volumn 20, Issue 7, 2013, Pages 1027-1033

  Ding, Zhenzhen ^a,b   Ou, Rongying ^a   Ni, Bing ^c   Tang, Jun ^d   Xu, Yunsheng ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b The People's Hospital of Yuyao   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d The 105th Hospital of PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

E7[11-20] PEPTIDE VACCINE; EPITOPE; FREUND ADJUVANT; GAMMA INTERFERON; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 70; HLA A2 ANTIGEN; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EX VIVO STUDY; FEMALE; HLA A2 GENE; IMMUNOGENICITY; IMMUNOMODULATION; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TRANSGENIC MOUSE; TUMOR CELL DESTRUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A2 ANTIGEN; HSP110 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84880493273     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00721-12     Document Type: Article

References (49)

1. Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, Lipetz C, Evans AS, Mason M. 2001. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 19:2549-2556. (Pubitemid 32234271)
2. Bernat A, Avvakumov N, Mymryk JS, Banks L. 2003. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 22:7871-7881. (Pubitemid 37175851)
3. Choo CK, Ling MT, Suen CK, Chan KW, Kwong YL. 2000. Retrovirus-mediated delivery of HPV16 E7 antisense RNA inhibited tumorigenicity of CaSki cells. Gynecol. Oncol. 78:293-301.
4. Zheng Y, Zhang Y, Ma Y, Wan J, Shi C, Huang L. 2008. Enhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular region. J. Microbiol. 46:728-736.
5. Davidson JS, Demsey D. 2012. Atypical fibroxanthoma: clinicopathologic determinants for recurrence and implications for surgical management. J. Surg. Oncol. 105:559-562.
6. Liao JB, Jean S, Wilkinson-Ryan I, Ford AE, Tanyi JL, Hagemann AR, Lin LL, McGrath CM, Rubin SC. 2011. Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: a clinically recalcitrant entity. Gynecol. Oncol. 120:108-112.
7. Liao SJ, Hu XJ, Han LF, Jiang XF, Xia X, Wang W, Lu YP, Wang SX, Ma D. 2009. Preparation of human papillomavirus 16 E7 peptide vaccine and its effectiveness in vitro and in vivo. Zhonghua Fu Chan Ke Za Zhi 44:903-908. (In Chinese.)
8. Liu DW, Yang YC, Lin HF, Lin MF, Cheng YW, Chu CC, Tsao YP, Chen SL. 2007. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients. J. Virol. 81:2869-2879.
9. Schreurs MW, Scholten KB, Kueter EW, Ruizendaal JJ, Meijer CJ, Hooijberg E. 2003. In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J. Immunol. 171:2912-2921. (Pubitemid 37093512)
10. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM. 1993. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:2242-2249. (Pubitemid 23265889)
11. Brinkman JA, Hughes SH, Stone P, Caffrey AS, Muderspach LI, Roman LD, Weber JS, Kast WM. 2007. Therapeutic vaccination for HPV induced cervical cancers. Dis. Markers 23:337-352. (Pubitemid 47015793)
12. Kanodia S, Da Silva DM, Kast WM. 2008. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int. J. Cancer 122:247-259. (Pubitemid 350234709)
13. Lazoura E, Apostolopoulos V. 2005. Insights into peptide-based vaccine design for cancer immunotherapy. Curr. Med. Chem. 12:1481-1494. (Pubitemid 40872573)
14. Scheibenbogen C, Letsch A, Schmittel A, Asemissen AM, Thiel E, Keilholz U. 2003. Rational peptide-based tumour vaccine development and T cell monitoring. Semin. Cancer Biol. 13:423-429. (Pubitemid 38156134)
15. Lazoura E, Apostolopoulos V. 2005. Rational peptide-based vaccine design for cancer immunotherapeutic applications. Curr. Med. Chem. 12: 629-639. (Pubitemid 40331056)
16. Meng WS, Butterfield LH. 2002. Rational design of peptide-based tumor vaccines. Pharm. Res. 19:926-932. (Pubitemid 34804233)
17. Ohno S, Kohyama S, Taneichi M, Moriya O, Hayashi H, Oda H, Mori M, Kobayashi A, Akatsuka T, Uchida T, Matsui M. 2009. Synthetic peptides coupled to the surface of liposomes effectively induce SARS coro-navirus- specific cytotoxic T lymphocytes and viral clearance in HLAA*0201 transgenic mice. Vaccine 27:3912-3920.
18. Behr TM, Gotthardt M, Barth A, Behe M. 2001. Imaging tumors with peptide-based radioligands. Q. J. Nucl. Med. 45:189-200. (Pubitemid 32640394)
19. Montomoli E, Piccirella S, Khadang B, Mennitto E, Camerini R, De Rosa A. 2011. Current adjuvants and new perspectives in vaccine formulation. Expert Rev. Vaccines 10:1053-1061.
20. Gauthier A, Martin-Escudero V, Moore L, Ferko N, de Sanjose S, Perez-Escolano I, Catala-Lopez F, Ferrer E, Bosch FX. 2008. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain. Eur. J. Public Health 18:674-680.
21. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, Dubin G; HPV Vaccine Adolescent Study Investigators Network. 2007. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J. Adolesc. Health 40:564-571. (Pubitemid 46771257)
22. Wang XY, Manjili MH, Park J, Chen X, Repasky E, Subjeck JR. 2004. Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins. Methods 32:13-20. (Pubitemid 37421174)
23. Goeckeler JL, Petruso AP, Aguirre J, Clement CC, Chiosis G, Brodsky JL. 2008. The yeast Hsp110, Sse1p, exhibits high-affinity peptide binding. FEBS Lett. 582:2393-2396.
24. Easton DP, Kaneko Y, Subjeck JR. 2000. The hsp110 and Grp1 70 stress proteins: newly recognized relatives of the Hsp70s. Cell Stress Chaperones 5:276-290.
25. Kim HL, Sun X, Subjeck JR, Wang XY. 2007. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. Cancer Immunol. Immunother. 56:1097-1105. (Pubitemid 46675302)
26. Manjili MH, Henderson R, Wang XY, Chen X, Li Y, Repasky E, Kazim L, Subjeck JR. 2002. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res. 62: 1737-1742. (Pubitemid 34408496)
27. Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, Subjeck JR. 2003. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J. Immunol. 171:4054-4061. (Pubitemid 37238680)
28. Wang XY, Chen X, Manjili MH, Repasky E, Henderson R, Subjeck JR. 2003. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100. Cancer Res. 63:2553-2560. (Pubitemid 36605196)
29. Ren F, Xu Y, Mao L, Ou R, Ding Z, Zhang X, Tang J, Li B, Jia Z, Tian Z, Ni B, Wu Y. 2010. Heat shock protein 110 improves the antitumor effects of the cytotoxic T lymphocyte epitope E7(49 -57) in mice. Cancer Biol. Ther. 9:134-141.
30. Kast WM, Brandt RM, Drijfhout JW, Melief CJ. 1993. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J. Immunother. Emphasis Tumor Immunol. 14:115-120. (Pubitemid 23297423)
31. Liu WJ, Liu XS, Zhao KN, Leggatt GR, Frazer IH. 2000. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology 273:374-382. (Pubitemid 30642572)
32. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ, Kast WM. 1995. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154:5934-5943.
33. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. 1992. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups, p 1065-1220. In Tsuji K, Aizawa M, Sasazuki T (ed), HLA 1991: proceedings of the Eleventh International Histocompatibility Workshop and Conference, Oxford University Press, Oxford, United Kingdom.
34. Liang B, Zhu L, Liang Z, Weng X, Lu X, Zhang C, Li H, Wu X. 2006. A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China. Cell. Mol. Immunol. 3:453-458.
35. He Y, Mao L, Lin Z, Deng Y, Tang Y, Jiang M, Li W, Jia Z, Wang J, Ni B, Wu Y. 2008. Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy. Mol. Immunol. 45:2455-2464.
36. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. 1996. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:21-26. (Pubitemid 26010379)
37. + T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice. Vaccine 30:3519-3525.
38. Peng S, Trimble C, He L, Tsai YC, Lin CT, Boyd DA, Pardoll D, Hung CF, Wu TC. 2006. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther. 13:67-77. (Pubitemid 41823853)
39. Murshid A, Gong Calderwood JSK. 2008. Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation. Expert Rev. Vaccines 7:1019-1030.
40. Segal BH, Wang XY, Dennis CG, Youn R, Repasky EA, Manjili MH, Subjeck JR. 2006. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov. Today 11:534-540. (Pubitemid 43732542)
41. Srivastava PK, Callahan MK, Mauri MM. 2009. Treating human cancers with heat shock protein-peptide complexes: the road ahead. Expert Opin. Biol. Ther. 9:179-186.
42. Heike M, Noll B, Meyer zum Buschenfelde KH. 1996. Heat shock protein-peptide complexes for use in vaccines. J. Leukoc. Biol. 60:153-158. (Pubitemid 26300997)
43. Li Z. 1997. Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines. Semin. Immunol. 9:315-322. (Pubitemid 28077729)
44. Hoffmann TK, Arsov C, Schirlau K, Bas M, Friebe-Hoffmann U, Klussmann JP, Scheckenbach K, Balz V, Bier H, Whiteside TL. 2006. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int. J. Cancer 118:1984-1991.
45. Youde SJ, McCarthy CM, Thomas KJ, Smith KL, Man S. 2005. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. Int. J. Cancer 114:606-612. (Pubitemid 40349620)
46. Schreurs MW, Kueter EW, Scholten KB, Lemonnier FA, Meijer CJ, Hooijberg E. 2005. A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope. Vaccine 23:4005-4010. (Pubitemid 40800659)
47. Oh HJ, Easton D, Murawski M, Kaneko Y, Subjeck JR. 1999. The chaperoning activity of hsp110. Identification of functional domains by use of targeted deletions. J. Biol. Chem. 274:15712-15718.
48. Wang XY, Kazim L, Repasky EA, Subjeck JR. 2001. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J. Immunol. 166:490-497. (Pubitemid 32038468)
49. Oh HJ, Chen X, Subjeck JR. 1997. Hsp110 protects heat-denatured proteins and confers cellular thermoresistance. J. Biol. Chem. 272:31636-31640. (Pubitemid 28013309)